drugset
Drugs / CX-5461
last change Dec 2025 re-read 2 minutes ago

CX-5461

also known as Pidnarulex

Small molecule

Developed for
metastatic malignant neoplasm · Burkitt lymphoma · cancer · castration-resistant prostate carcinoma · colorectal adenocarcinoma · diffuse large B-cell lymphoma · female breast carcinoma · HER2 positive breast carcinoma
+6 more · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · hormone receptor-positive breast cancer · invasive breast carcinoma · neoplasm · refractory malignant neoplasm · triple-negative breast carcinoma
Investigated by
National Cancer Institute (NCI) · Senhwa Biosciences, Inc. · Canadian Cancer Trials Group · Peter MacCallum Cancer Centre, Australia · Stand Up To Cancer

Trials 7 · a red edge is where a trial was stopped

today NCT07147231 · Ph 1/2 NCT07069699 · Ph 1/2 NCT07137416 · Ph 1 NCT06606990 · Ph 1 NCT05425862 · Ph 1 NCT04890613 · Ph 1 NCT02719977 · Ph 1
20172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07137416 Oct 2026 → Jan 2028 expected HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma +3 National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT06606990 Jul 2025 → Dec 2026 expected metastatic malignant neoplasm National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT05425862 Oct 2022 → Jul 2024 castration-resistant prostate carcinoma Peter MacCallum Cancer Centre, Australia Suspended No outcome recorded
Phase 1 NCT04890613 Sep 2021 → Mar 2027 expected neoplasm Senhwa Biosciences, Inc. Recruiting No outcome recorded
Phase 1 NCT02719977 Jun 2016 → Jan 2020 cancer Canadian Cancer Trials Group Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07147231 Dec 2026 → Sep 2027 expected colorectal adenocarcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1/2 NCT07069699 Oct 2026 → Jan 2030 expected Burkitt lymphoma, diffuse large B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement National Cancer Institute (NCI) Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as CX-5461 “CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination-deficient models.” PMID 35750695 ↗ Jun 2022
2

NCT02719977 ↗

NCT04890613 ↗
Known as Pidnarulex ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137416 ↗
4

NCT06606990 ↗

NCT07069699 ↗

NCT07147231 ↗

NCT05425862 ↗
Action Inhibit “designed to stop the action of a particular protein in the body called Polymerase I” NCT05425862 ↗
Modality Small molecule “synthetically-derived small molecule” NCT04890613 ↗
1

CHEMBL4303309 ↗
Route Intravenous “CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks.” NCT02719977 ↗